Welcome to our dedicated page for NanoString Technologies news (Ticker: NSTG), a resource for investors and traders seeking the latest updates and insights on NanoString Technologies stock.
NanoString Technologies, Inc. (NASDAQ: NSTG) is a renowned provider of life science tools for translational research and molecular diagnostics. Established in 2008, NanoString's technology is pivotal in enabling a diverse array of basic research, translational medicine, and in vitro diagnostics applications. The company's flagship product, the nCounter® Analysis System, is celebrated for its ability to profile the expression of hundreds of genes, miRNAs, or copy number variations simultaneously with high sensitivity and precision. This system has been referenced in over 300 peer-reviewed publications, underscoring its widespread adoption and scientific credibility.
The nCounter® system's versatility extends to diagnostic use as the nCounter Dx Analysis System, further solidifying NanoString's footprint in the molecular diagnostics landscape. The technology stands out for its cost-effectiveness and efficiency, making it a valuable tool for applications such as biomarker discovery and validation, as well as other translational research endeavors.
Among recent developments, NanoString Technologies has been embroiled in significant litigation with 10x Genomics, Inc. Notably, the European Unified Patent Court (UPC) declined to issue a second preliminary injunction against NanoString, allowing the company to continue its operations in specific jurisdictions. However, injunctions from the Regional Court Munich I and the UPC still impose restrictions on the sale and service of NanoString's CosMx Spatial Molecular Imager (SMI) instruments and reagents for RNA detection in Europe.
The legal battles extend to the United States, where 10x Genomics has filed multiple suits against NanoString alleging patent infringement related to the GeoMx Digital Spatial Profiler and the CosMx SMI. Recently, a jury in the U.S. District Court for the District of Delaware awarded 10x Genomics over $31 million in damages, asserting that NanoString's GeoMx products willfully infringed on several patents.
Despite these legal challenges, NanoString continues to thrive as a leader in its field, providing essential tools that drive significant discoveries in oncology, immunology, neuroscience, and beyond. The company's commitment to advancing human health through molecular diagnostics and translational research tools remains unwavering.
NanoString Technologies, Inc. (NASDAQ:NSTG) reported strong momentum in spatial biology, showing a 50% increase in orders YoY for over 105 instruments in Q4 2022. Revenue reached $34.4 million, with spatial biology contributing $14.8 million. The company recorded full-year revenues of $127.3 million. Notably, $40 million in CosMx orders is in backlog, positioning them for continued growth in 2023, with projected revenues between $170 million and $180 million. However, the company anticipates an adjusted EBITDA loss of $65 to $75 million. Cash reserves stood at $196.5 million as of year-end 2022.
NanoString Technologies (NASDAQ:NSTG) announced its participation in the 43rd Annual Cowen Health Care Conference, scheduled for March 6-8, 2023. CEO Brad Gray will present on March 7, 2023, at 1:30 PM ET. Interested investors can access the live webcast via the company’s investor section at www.nanostring.com. The replay will be available one hour post-presentation and archived for 60 days. NanoString is recognized for its spatial biology tools, including the GeoMx Digital Spatial Profiler and the nCounter Analysis System, used widely in research, enhancing the understanding of biological processes.
NanoString Technologies, Inc. (NASDAQ:NSTG) will report its fourth quarter and fiscal year 2022 operating results on February 28, 2023, after market close. A conference call to discuss these results will be held at 4:30 PM ET the same day. Investors are encouraged to register in advance for the call via the provided link, which will also offer access to a replay starting at 7:30 PM ET on the reporting date and lasting until March 14, 2023. NanoString continues to innovate in spatial biology, with products like the GeoMx® Digital Spatial Profiler and CosMx™ Spatial Molecular Imager enhancing research capabilities.
NanoString Technologies has launched the Spatial Atlas of Human Anatomy (SAHA) initiative in collaboration with Weill Cornell Medicine. This ambitious project aims to create multicellular and single-cell maps of 30 healthy organs from a diverse adult population, encompassing over 250 million cells. The SAHA will develop a comprehensive database of spatial biology, offering insights into organ development and health.
Key technologies used include the GeoMx Digital Spatial Profiler and CosMx Spatial Molecular Imager, which will facilitate high-resolution analysis. The dataset will be made available publicly, promoting further research in spatial precision medicine.
NanoString Technologies (NASDAQ: NSTG) has released a new dataset generated by its CosMx™ Spatial Molecular Imager (SMI), showcasing its high sensitivity and specificity in analyzing liver tissue. The dataset includes over 800,000 single cells and approximately 700 million transcripts, highlighting the capability to detect an average of 1,150 transcripts per cell and 676 unique genes with more than 99% specificity. This technology enables comprehensive cell and tissue analysis in cancer research, particularly in hepatocellular carcinoma. Moreover, the data is available in an open-source format via the AtoMx™ Spatial Informatics Platform, enhancing research accessibility.
NanoString Technologies (NASDAQ:NSTG) reported strong Q4 results with over
NanoString Technologies (NASDAQ: NSTG) announced that its CosMx™ Spatial Molecular Imager was featured in National Geographic Magazine's January edition. The article discussed research from Wake Forest University, which utilized the CosMx SMI to examine brain tissue from Alzheimer’s patients, revealing critical insights into aging and cellular senescence. The CosMx SMI enables high-resolution imaging of over 1,000 RNA and 64 protein analytes, allowing researchers to create detailed cellular maps. This technology enhances research capabilities in cellular analysis and Alzheimer’s disease studies.
NanoString Technologies, Inc. (NASDAQ:NSTG) has announced its participation at the 41st Annual J.P. Morgan Healthcare Conference on January 11th, 2023, at 3:00pm PT. CEO Brad Gray will present during the event, which can be accessed via a live webcast on the company’s website. A replay will be available one hour post-presentation and archived for 60 days. NanoString is known for its innovative life science tools, including the GeoMx® Digital Spatial Profiler and CosMx™ Spatial Molecular Imager, enabling advanced research in spatial biology.
FAQ
What is the market cap of NanoString Technologies (NSTG)?
What is NanoString Technologies' primary business?
What is the nCounter® Analysis System?
What are some applications of NanoString's technology?
Has NanoString been involved in any legal issues recently?
What was the outcome of the recent lawsuit in the U.S. District Court for the District of Delaware?
What is the significance of the nCounter Dx Analysis System?
How many peer-reviewed publications have cited the nCounter® system?
What is the cost advantage of NanoString's technology?
What are the legal implications of the injunctions against NanoString in Europe?
How does NanoString contribute to advancements in human health?
